about
Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activityPredicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats.Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers.Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human.PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model.Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibodyPharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion systemImprovement of pharmacokinetic properties of therapeutic antibodies by antibody engineering
P50
Q27678516-6818BD9B-1481-4744-98A6-36EA8196704FQ28487387-0628F014-B907-4EC8-A27F-9A64B7E4BA6AQ31091923-CD09D918-6F11-494A-B0AE-60DB9E9D7219Q34718085-B4F493AA-975B-498D-AAFD-DE85BCE3B518Q38666667-3C9E64BD-B0A0-4EDF-8FBB-18D7D01BF5A7Q38728589-D5FD9943-2733-4A7C-B312-F121059FCC34Q38951490-BB6B4F25-4815-4B74-BA63-DAF3FD898EFCQ41104888-B2B8B8ED-8974-4BE0-868C-29E8B2F1DEEBQ41953134-319000CD-6F0D-44BE-9AC9-FA3439167065Q42584647-0701500F-0211-4B77-A0BC-01E4223852B8Q44680126-47D2E41E-1A28-472B-A443-D78BF37C4EC1Q45162698-01BAE57E-8D79-4034-A3F1-6D61D289B6BCQ45864199-C9FF439D-C3AC-43FB-A88B-FA1D1703CD3FQ46562422-5A61FE78-42D4-467C-900B-B2EFA3A64EA6Q46866013-D6A9E9E8-FC66-48DE-9430-51107CBCDA01Q47418350-699420C8-5EEF-42B5-972E-C7ABCEC7092AQ49645437-BF9F9092-1322-43C6-BB0C-FFC8CF56BAA2Q53213559-4F0BABA7-71CE-4ABF-B466-7630AC90B480Q60929655-08568A62-B826-42AC-96D8-EE6813A87E35Q80099969-989A4A07-92B5-4A71-B3A8-697B90B5F3C0Q93343703-9708ECE7-D5D9-40FA-B58B-B2596358227D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Kenta Haraya
@en
Kenta Haraya
@nl
type
label
Kenta Haraya
@en
Kenta Haraya
@nl
prefLabel
Kenta Haraya
@en
Kenta Haraya
@nl
P31
P496
0000-0002-9142-5607